Article
Adding local gyro-knife radiotherapy to EGFR-TKI improves outcomes in EGFR-mutant NSCLC.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology - 1 Sept 2026
Zhang Zhinan, Tao Xue, Ju Hong, Sun Xiaoyan, Lu Shuangling, Tong Bin
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR-mutant non-small cell lung cancer (NSCLC), yet acquired resistance, particularly local progression, remains a major clinical challenge. The additive role of local stereotactic radiotherapy (e.g., Gyro-Knife-based SBRT) is not well defined. METHODS: In this retrospective cohort study, 82...
Topics
Join the communities discussing this publication.
